EuroLab Magazine, ScientistLive December 2018
Going Beyond CHO
DGIwire December 3, 2018
Is a Fungus Among Us the Key to Tomorrow’s Biologic Drugs?
DGIwire November 26, 2018
Building Better Biologics: A Challenge for the Biopharma Industry
Science, November 16, 2018
Protein expression, revisited
R&D Magazine / Pharmaceutical Processing, November 5, 2018
Fungal Strain Technology Could Disrupt Bio-Manufacturing Industry
BioPharm International, November 1, 2018
Media Requirements for Different Cell Sources
LSX Leaders (formerly known as BiotechandMoney), October 2018
Dyadic International: Working to Change the Game in Biopharma Manufacturing
PharmTech.com, October 5, 2018
Biologic Drugs Challenge the Biopharma Industry
Yahoo Finance, October 4, 2018
Undervalued Stocks You Can’t Afford to Miss
Biocompare, September 27, 2018
CHO Cells: Beginning of the End or End of the Beginning?
Pharmaceutical Manufacturing, September 25, 2018
Ditching the Model T for a Faster Ride
BioPharma-Reporter.com, September 24, 2018
CHO cells the 1900s model car in a 2020 Tesla world, says Dyadic
The Medicine Maker magazine, September 2018
The CHO’s Over: An Inflexion Point
ContractPHARMA, September 18, 2018
Dyadic, Sanofi in Research Collaboration
BioProcess International, September 12, 2018
Sanofi deal shows demand for CHO alternatives, says Dyadic
BioPharmInternational.com, September 20, 2018
Sanofi Partners with Dyadic to Research Fungus-Based Expression Platform
PharmTech.com August 2, 2018
The Challenge of Building Better Biologic Drugs
BioSpace, August 7, 2018
From “Jeans to Genes”: Mark Emalfarb Thinks He Can Revolutionize Biopharma Manufacturing
BioPharm International, August 1, 2018
“The Search for Next-Gen Expression Systems”
PharmTech.com, July 2, 2018
“The Search for Next-Gen Expression Systems“
Chemistry & Industry, July 6, 2018
“Access and Affordability”
BioProcess International, June 5, 2018
“Dyadic to Develop Biosimilars Using CHO-Challenging Expression System“
BioProcess International, May 2018
“The Future of Monoclonal Antibody Manufacturing – Incremental Improvement or Industrial Revolution?”
TransTech Alert March 2018
Mutant-Fungus Attack on Biologics Industry Could Make Investors Rich
BioPharma-Reporter.com April 4, 2018
Dyadic confident Big Biopharma will move away from CHO cell reliance
BioPharma-Reporter.com February 21, 2018
“There is a new kid on the block to rival E. Coli, CHO and yeast” says Dyadic International as it collaborates to widen the use of its C1 expression technology
BioPharma-Reporter.com, February 21, 2018
Dyadic enters R&D deal for its fungus-based expression system
